Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in ...
Congressional attendance was up in 2025, in spite of off-year elections, a number of members beset with health crises and the political turmoil that marked President Donald Trump’s return to the White ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results